

08/28/01

13

1

Sheet 2 of 3

FORM PTO-1449 U.S. Dept. of Commerce Patent and Trademark Office LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)	Atty Docket No. P1256R3	Serial No. 09/209,023
	Applicant Paton et al.	
	Filing Date 10 Dec 1998	Group 1642

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	101	5,910,486	08.06.99	Curriel et al.			
	102	5,922,845	13.07.99	Deo et al.			
	103	5,939,531	17.08.99	Wels et al.			
	104	5,977,322	02.11.99	Marks et al.			
	105	5,985,553	16.11.99	King et al.			
	106	6,015,567	18.01.00	Hudziak et al.			
	107	6,028,059	22.02.00	Curriel et al.			
	108	6,054,297	25.04.00	Carter et al.			
	109	6,054,561	25.04.00	Ring, D. B.			
	110	6,123,939	26.09.00	Shawver et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No	
ALH	111	0,599,274 A1	01.06.94	EPO				
ALH	112	711,565	26.08.98	EPO				
ALH	113	2,895,105B2	24.05.99	JAPAN (ENGLISH ABSTRACT AND CLAIMS)				
ALH	114	95,006,982B2	30.01.95	JAPAN (ENGLISH ABSTRACT AND CLAIMS)				
ALH	115	3-240498	25.10.91	JAPAN (ENGLISH ABSTRACT ATTACHED)				
ALH	116	5-117165	14.05.93	JAPAN (ENGLISH ABSTRACT ATTACHED)				
ALH	117	5-170667	09.07.93	JAPAN (ENGLISH ABSTRACT ATTACHED)				
ALH	118	5-213775	24.08.93	JAPAN (ENGLISH ABSTRACT ATTACHED)				
ALH	119	5-317084	03.12.93	JAPAN (ENGLISH ABSTRACT ATTACHED)				
ALH	120	7-59588	07.03.95	JAPAN (ENGLISH ABSTRACT ATTACHED)				
ALH	121	2,761,543B2	04.06.98	JAPAN (TRANSLATION ATTACHED)				
	122	WO 92/10573	25.06.92	PCT				
	123	WO 93/12220	24.06.93	PCT				
	124	WO 93/21232	28.10.93	PCT				
	125	WO 93/21319	28.10.93	PCT				
	126	WO 94/28127	08.12.94	PCT				
	127	WO 95/16051	15.06.95	PCT				
	128	WO 95/17507	29.06.95	PCT				
	129	WO 95/28485	26.10.95	PCT				
	130	WO 96/18409	20.06.96	PCT				
	131	WO 97/27848	07.08.97	PCT				
	132	WO 97/38731	23.10.97	PCT				
	133	WO 98/17797	30.04.98	PCT				

Examiner 	Date Considered 12/24/03
--	------------------------------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Docket No.
P1256R3

Serial No.
09/209,023

LIST OF DISCLOSURES CITED BY APPLICANT
(Use several sheets if necessary)

Applicant
Paton et al.

Filing Date
10 Dec 1998

Group
1642

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes No
	134 WO 98/45479	15.10.98	PCT			
	135 WO 99/31140	24.06.99	PCT			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

Aut	136	Baselga and Mendelsohn, "Receptor Blockade With Monoclonal Antibodies As Anti-Cancer Therapy" <u>Pharmac. Ther.</u> 64:127-154 (1994)
	137	De Santes et al., "Radiolabeled Antibody Targeting of the HER-2/neu Oncoprotein" <u>Cancer Research</u> 52:1916-1923 (1992)
	138	Ilgen et al., "Characterization of anti-HER/2 antibodies which inhibit the growth of breast tumor cells in vitro" <u>Proceedings of the American Association for Cancer Research</u> (abstract #3209) 37:470 (Mar 1996)
	139	Lewis et al., "Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness" <u>Cancer Research</u> 56:1457-1465 (Mar 15, 1996)
	140	Masui et al., "Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies" <u>Cancer Research</u> 44(3):1002-1007 (Mar 1984)
	141	Masuko et al., "A murine Monoclonal Antibody That Recognizes an Extracellular Domain of the Human c-erbB-2 Protooncogene Product" <u>Jpn J. Cancer Res.</u> 80:10-14 (January 1989)
	142	McCann et al., "c-erbB-2 Oncoprotein Expression in Primary Human Tumors" <u>Cancer</u> 65(1):88-92 (Jan 1, 1990)
	143	Rodeck et al., "Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors" <u>J. Cellular Biochem.</u> 35(4):315-320 (1987)
	144	Schlom, J., "Monoclonal Antibodies: They're More and Less Than You Think" <u>Molecular Foundations of Oncology</u> , Broder, S. ed., Baltimore, MD:Williams & Wilkins, Chapter 6, pps. 95-134 (1991)
	145	Slivkowski et al., "A humanized monoclonal antibody for the treatment of HER2 overexpressing breast cancer" <u>Proceedings of the American Association for Cancer Research</u> (abstract only) 37:625-626 (Mar 1996)
	146	Zhang et al., "Shared antigenic epitopes and pathobiological functions of anti-p185 ^{HER2/neu} monoclonal antibodies" <u>Experimental and Molecular Pathology</u> 67:15-25 (1999)

Examiner

Anne L. Haller

Date Considered

12/28/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1256R3	Serial No. 09/209,023
		Applicant Paton et al.	
		Filing Date 10 Dec 1998	Group 1642

U.S. PATENT DOCUMENTS						
Examiner Initials		Document Number	Date	Name	Class	Filing Date
ALH	170	4,017,471	12.04.77	Davies, D.		

FOREIGN PATENT DOCUMENTS						
Examiner Initials		Document Number	Date	Country	Class	Translation Yes No
ALH	171	WO 01/87334	22.11.01	PCT		

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)						
ALH	172	Albanell et al., "Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer" <u>Drugs of Today</u> 35(12):931-946 (1999)				
ALH	173	"Aminoglutethimide" <u>Martindale - The Complete Drug Reference - Monographs</u> (website version of product information) pps. 1-4 (2003)				
ALH	174	Argiris and DiGiovanna, "Synergistic interactions between tamoxifen and HERCEPTIN TM" <u>Proceedings of the American Association for Cancer Research</u> (Abstract #4565) 41:718 (Mar 2000)				
ALH	175	"Arimidex (anastrozole) Tablets" <u>Physicians' Desk Reference</u> (website version of product information) pps. 1-14 (2003)				
ALH	176	"Aromasin (exemestane tablets)" <u>Physicians' Desk Reference</u> (website version of product information) pps. 1-9 (2003)				
ALH	177	Benz et al., "Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu" <u>Breast Cancer Research & Treatment</u> 24(2):85-95 (1992)				
ALH	178	Brueggemeier, R., "Aromatase, aromatase inhibitors, and breast cancer" <u>American Journal of Therapeutics</u> 8(5):333-344 (Sep-Oct 2001)				
ALH	179	"A concerted attack on cancer" <u>Scrip Magazine</u> 2617(Review Issue 2000):68-70 (Feb 14, 2001)				
ALH	180	Dati et al., "Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells" <u>Oncogene</u> 5(7):1001-1006 (Jul 1990)				
ALH	181	"Femara (letrozole tablets)" <u>Physicians' Desk Reference</u> (website version of product information) pps. 1-13 (2003)				
ALH	182	Grem et al., "A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group Pilot Study" <u>American Journal of Clinical Oncology</u> 11(5):528-534 (Oct 1988)				
ALH	183	Hamilton and Piccart, "The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2" <u>Annals of Oncology</u> 11(6):647-663 (Jun 2000)				
ALH	184	Kaufmann et al., "Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial" <u>Journal of Clinical Oncology</u> 18(7):1399-1411 (Apr 2000)				
ALH	185	Konecny et al., "New drugs in breast cancer therapy: Current position and future perspectives" <u>Gynaekologisch-Geburtshilfliche Rundschau</u> (English language abstract only) 37(2):54-61 (Oct 1997)				
ALH	186	Kunisue et al., "Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2" <u>British Journal of Cancer</u> 82(1):46-51 (Jan 2000)				
ALH	187	Leyland-Jones et al., "Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer" (Abstract #35. Presented at the 2002 SABCS meeting.) (2002)				

Examiner	Date Considered 12/29/03
----------	---

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

USCOMM-DC 80-398.

FORM PTO-1449 - -

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1256R3

Serial No.

09/209,023

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Paton et al.

Filing Date

10 Dec 1998

Group	Mean	SD	95% CI
Control	1.00	0.00	1.00
Low	1.00	0.00	1.00
High	1.00	0.00	1.00

1642

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
ALH	160	6,214,863	10.04.01	Bissery, M.			
ALH	161	6,333,348	25.12.01	Vogel et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No	
ALH	162	WO 00/61185	19.10.00	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

[illegible]

Examiner	<i>Ann L. Heller</i>	Date Considered	12/21/03
----------	----------------------	-----------------	----------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.